- Accesswire•yesterdayResearch Reports Initiated on Healthcare Stocks Resverlogix, Immunovaccine, IntelliPharmaCeutics International, and Aeterna Zentaris
LONDON, UK / ACCESSWIRE / February 24, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected ...
- Business Wire•11 days agoAeterna Zentaris Announces Zoptrex™ Presentation in Prostate Cancer at 2017 Genitourinary Cancers Symposium
Aeterna Zentaris Inc. today announced that a poster entitled, “A phase II trial of zoptarelin doxorubicin in castration-and taxane-resistant prostate cancer”, will be presented during the 2017 Genitourinary Cancers Symposium’s “Translating Research to Value-based and Patient-centric Care” by lead investigator, and co-author of the presentation, Jacek Pinski, MD, PhD, USC Norris Comprehensive Cancer ...
- Business Wire•12 days ago
Aeterna Zentaris Inc. today announced that, following a comprehensive review of data obtained from the confirmatory Phase 3 clinical trial of Macrilen™ for the evaluation of growth hormone deficiency in adults , using the insulin tolerance test as a comparator, it concluded that Macrilen™ demonstrated performance supportive of achieving registration with the U.S.
AEZ.TO : Summary for AETERNA ZENTARIS INC. - Yahoo Finance
Aeterna Zentaris Inc. (AEZ.TO)
Toronto - Toronto Delayed Price. Currency in CAD
Add to watchlist
|Day's Range||3.95 - 4.06|
|52 Week Range||3.10 - 7.32|
|PE Ratio (TTM)||-1.36|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|